Neurotech Pharmaceuticals Inc.
BiotechNeurotech Pharmaceuticals Inc. is a biotechnology company focused on Ophthalmology.
Neurotech Pharmaceuticals Inc.'s Key Drugs
Neurotech Pharmaceuticals Inc.'s core commercial portfolio centers on encelto, spanning Ophthalmology — its most strategically important drugs approved in the last 15 years.
Neurotech Pharmaceuticals Inc.'s Recent FDA Approvals
Neurotech Pharmaceuticals Inc. secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
Neurotech Pharmaceuticals Inc.'s Therapeutic Areas
Neurotech Pharmaceuticals Inc.'s approved drugs and pipeline span 1 therapeutic area, led by Ophthalmology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Neurotech Pharmaceuticals Inc.'s Top Competitors
Neurotech Pharmaceuticals Inc.'s closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and OTSUKA ICU MEDCL. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Neurotech Pharmaceuticals Inc. Pipeline Snapshot
Neurotech Pharmaceuticals Inc. has 8 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 3 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • encelto leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Ophthalmology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/3 completed
- • Speed: 53 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2025-03-04
- Latest
- 2025-03-04
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges